Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study

Gilad Sherman; Gabriella S Lamb; Tanvi S Sharma; Elizabeth C Lloyd; Jerod Nagel; Nada N Dandam; Carlos R Oliveira; Hassan S Sheikha; Brenda I Anosike; Philip Lee; Surabhi B Vora; Karisma Patel; Paul K Sue; Beenish Rubbab; April M Yarbrough; Lakshmi Ganapathi; Mari M Nakamura

doi:10.1093/jpids/piac124

Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study

J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):152-155. doi: 10.1093/jpids/piac124.

Authors

Gilad Sherman^{1

2}, Gabriella S Lamb^{1

2}, Tanvi S Sharma^{1

2}, Elizabeth C Lloyd³, Jerod Nagel⁴, Nada N Dandam⁴, Carlos R Oliveira⁵, Hassan S Sheikha⁵, Brenda I Anosike⁶, Philip Lee⁶, Surabhi B Vora⁷, Karisma Patel⁸, Paul K Sue⁸, Beenish Rubbab⁸, April M Yarbrough⁹, Lakshmi Ganapathi^{1

2}, Mari M Nakamura^{1

2

10}

Affiliations

¹ Division of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.
² Department of Pediatrics, Harvard Medical School.
³ Department of Pediatrics, University of Michigan and CS Mott Children's Hospital, Ann Arbor, Michigan, USA.
⁴ Department of Pharmacy, University of Michigan and CS Mott Children's Hospital, Ann Arbor, Michigan, USA.
⁵ Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
⁶ Department of Pediatrics, Children's Hospital at Montefiore, New York, New York, USA.
⁷ Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, Washington, USA.
⁸ Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
⁹ Department of Pharmacy, Children's of Alabama, Birmingham, Alabama, USA.
¹⁰ Antimicrobial Stewardship Program, Boston Children's Hospital, Boston, MA, USA.

Abstract

Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.

Keywords: COVID-19; SARS-CoV-2; bamlanivimab and etesevimab; casirivimab and imdevimab; monoclonal antibodies; pediatric.

© The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: [email protected].

Publication types

Multicenter Study

MeSH terms

Antibodies, Monoclonal / therapeutic use
COVID-19*
Child
Hospitalization
Hospitals, Pediatric
Humans
Retrospective Studies

Substances

Antibodies, Monoclonal

Abstract

Publication types

MeSH terms

Substances

Grants and funding